Skip to main content
MyTrial AcademyFormerly FreeGCP
Account
FDA adopted · September 2025
Last updated September 2026

ICH E6(R3) vs FDA E6(R3): What Actually Changed?

FDA issued E6(R3) as final guidance in September 2025. The publication carries the ICH E6(R3) core inside an FDA wrapper with U.S.-specific context and an explicit nonbinding-guidance disclaimer.
View the full comparisonCommon questions
E6(R3) core
Shared
Guidance wrapper
FDA
Guidance status
Nonbinding

Side-by-side analysis

Key differences at a glance

FDA's September 2025 final guidance publishes the E6(R3) core with an FDA-specific wrapper, including U.S. contacts, a foreword, and the agency's nonbinding-guidance disclaimer.

CategoryICH E6(R3)FDA E6(R3)Impact
Document titleICH E6(R3) Good Clinical PracticeE6(R3) Good Clinical Practice: Guidance for IndustryMinimal
Legal status disclaimerNot present'Contains Nonbinding Recommendations' appears on most pagesNotable
ForewordMinimal introductory contextComprehensive foreword explaining ICH mission and FDA's role as Founding Regulatory MemberContextual
Regulatory contextInternational harmonization focusU.S. regulatory framework context with references to 21 CFR and 42 USCNotable
Contact informationGeneral ICH secretariatSpecific CDER and CBER contact details for inquiriesContextual
Alternative approachesNot explicitly addressedClarifies that sponsors may use alternative approaches if they satisfy applicable statutes and regulationsNotable
Scientific contentHarmonized E6(R3) core guidelinePublishes the E6(R3) core within an FDA guidance wrapperShared core
Core principlesRisk-based QM, flexibility, technology adoption, proportionalitySame E6(R3) quality-by-design and proportionality principlesShared core
Page layoutStreamlined international formatU.S. government document formatting with HHS/FDA brandingMinimal

Document title

Minimal

ICH E6(R3)

ICH E6(R3) Good Clinical Practice

FDA E6(R3)

E6(R3) Good Clinical Practice: Guidance for Industry

Legal status disclaimer

Notable

ICH E6(R3)

Not present

FDA E6(R3)

'Contains Nonbinding Recommendations' appears on most pages

Foreword

Contextual

ICH E6(R3)

Minimal introductory context

FDA E6(R3)

Comprehensive foreword explaining ICH mission and FDA's role as Founding Regulatory Member

Regulatory context

Notable

ICH E6(R3)

International harmonization focus

FDA E6(R3)

U.S. regulatory framework context with references to 21 CFR and 42 USC

Contact information

Contextual

ICH E6(R3)

General ICH secretariat

FDA E6(R3)

Specific CDER and CBER contact details for inquiries

Alternative approaches

Notable

ICH E6(R3)

Not explicitly addressed

FDA E6(R3)

Clarifies that sponsors may use alternative approaches if they satisfy applicable statutes and regulations

Scientific content

Shared core

ICH E6(R3)

Harmonized E6(R3) core guideline

FDA E6(R3)

Publishes the E6(R3) core within an FDA guidance wrapper

Core principles

Shared core

ICH E6(R3)

Risk-based QM, flexibility, technology adoption, proportionality

FDA E6(R3)

Same E6(R3) quality-by-design and proportionality principles

Page layout

Minimal

ICH E6(R3)

Streamlined international format

FDA E6(R3)

U.S. government document formatting with HHS/FDA branding

In-depth analysis

Understanding the differences

A detailed breakdown of each difference between the ICH and FDA versions, and what it means for clinical research professionals, sponsors, and investigators.

  1. FDA's 'nonbinding recommendations' disclaimer

    What changed

    The FDA publication displays 'Contains Nonbinding Recommendations' and states that the guidance represents FDA's current thinking, does not establish rights, and is not binding on FDA or the public. An alternative approach may be used if it satisfies applicable statutes and regulations.

    Practical implication

    Treat the guidance as the agency's recommended framework. Determine binding duties from applicable statutes, regulations, protocol commitments, and controlled procedures.

  2. ICH mission and harmonization context

    What changed

    The FDA's foreword provides extensive context about the International Council for Harmonisation (ICH), founded in 1990 to unite regulators and pharmaceutical industry globally. It explains how ICH ensures medicines are safe, effective, high-quality, and efficiently registered worldwide through consensus-based guidelines.

    Practical implication

    The foreword explains why the core guideline is harmonized while FDA still publishes it within the U.S. guidance framework.

  3. FDA-specific contact information

    What changed

    The FDA version includes specific contact details for the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). This provides clear channels for industry to seek clarification or submit questions about the guidance.

    Practical implication

    Use the contacts named in the FDA publication when the guidance directs readers to discuss an alternative approach.

  4. Alternative approaches, clarified

    What changed

    The FDA explicitly states that sponsors can use alternative approaches to those described in the guidance, provided they satisfy the requirements of applicable statutes and regulations. This flexibility is clarified upfront in the FDA version.

    Practical implication

    An alternative is not automatically acceptable; the applicable legal requirements still have to be satisfied.

  5. Document history presentation

    What changed

    Both versions include a document history table tracking the evolution from E6 through E6(R1), E6(R2), and now E6(R3). The FDA version integrates this within its introductory pages, while the ICH version presents it on a dedicated page.

    Practical implication

    Minimal practical difference: both provide the same historical context in slightly different formats.

  6. What E6(R3) changes for everyone

    What changed

    FDA's official E6(R3) page highlights increased flexibility for modern trial designs, quality by design and risk-based quality management, clarified sponsor and investigator responsibilities, proportionality, critical thinking, and support for technology and innovation.

    Practical implication

    Teach the harmonized core, then apply the regional legal, procedural, and study-specific context that governs the work.

The bottom line

What this means for your work

The FDA's adoption of ICH E6(R3) places the harmonized E6(R3) core inside the FDA guidance framework. Read the core alongside the FDA wrapper and the applicable legal and study-specific requirements rather than treating the guidance itself as a regulation.

Shared core

Harmonized E6(R3) guideline

FDA wrapper

U.S. context and legal status

Applicable law

Source of binding duties

Common questions

Clarity on guidance status, training, and adoption.

These FAQs focus on practical implications of the FDA's adoption of ICH E6(R3) and how it affects your training and documentation.

Do the FDA and ICH publications share the same E6(R3) core?
Yes. FDA's September 2025 final guidance publishes the ICH E6(R3) core guideline within an FDA guidance wrapper. The FDA publication adds U.S.-specific cover material, contacts, a foreword, nonbinding-guidance language, and section lettering. This page avoids claiming the files are byte-for-byte identical.
When did the FDA adopt ICH E6(R3)?
The ICH Assembly endorsed the Step 4 E6(R3) guideline on January 6, 2025. FDA announced its E6(R3) final guidance for industry in September 2025.
What are the main differences between ICH and FDA versions?
The FDA publication adds an FDA title page, CDER and CBER contact information, a foreword, 'Contains Nonbinding Recommendations' notices, and U.S.-style section lettering. Its standard disclaimer says the guidance represents FDA's current thinking and that an alternative approach may be used if it satisfies applicable statutes and regulations.
Do I need separate training for FDA vs ICH E6(R3)?
The publications share the E6(R3) core, so duplicate teaching of that core is generally unnecessary. U.S.-regulated work still benefits from the FDA wrapper and applicable legal context, and an employer, sponsor, protocol, or authority may set its own training requirements. MyTrial Academy teaches the E6(R3) core and distinguishes guidance from binding duties.
Why does the FDA version say 'nonbinding recommendations'?
FDA states that the document represents the agency's current thinking, does not establish rights, and is not binding on FDA or the public. An alternative approach may be used if it satisfies applicable statutes and regulations. Legally enforceable duties come from those statutes and regulations, not from the guidance label by itself.
Which version should I reference in my protocols?
Follow the applicable authority, protocol, sponsor procedures, and document-control conventions. For FDA-regulated work, the September 2025 FDA final guidance is the authoritative FDA publication. Multiregional studies may also identify the ICH Step 4 guideline and relevant regional adoptions.
What key updates does E6(R3) introduce?
FDA highlights greater flexibility for modern trial designs, data sources, and technology; stronger quality by design and risk-based quality management; clarified sponsor and investigator responsibilities; and proportionality, relevance, and critical thinking across the trial lifecycle.
How does this affect existing E6(R2) training?
FDA now publishes E6(R3) as its final guidance and lists E6(R2) among withdrawn or expired clinical-trial guidances. Training and document transitions should follow applicable authority dates, the study's stage, and organizational procedures rather than a universal Academy deadline.
Can I use the ICH version for FDA-regulated trials?
The ICH publication contains the harmonized core, but FDA-regulated work should consult the FDA-issued final guidance and applicable U.S. statutes and regulations. Which document a protocol or submission cites should follow the responsible authority and the organization's controlled procedures.
Does the 'nonbinding' language make GCP optional?
The guidance itself is nonbinding. That does not remove duties imposed by applicable statutes and regulations, an approved protocol, informed-consent and IRB requirements, contracts, or organizational procedures. The FDA disclaimer specifically says an alternative approach must still satisfy applicable statutes and regulations.
How does E6(R3) improve upon E6(R2)?
E6(R3) gives greater emphasis to flexible trial designs and technology, proactive quality by design, proportionate risk-based quality management, clearer sponsor and investigator responsibilities, and critical thinking. Those themes are described on FDA's official E6(R3) guidance page and in the guideline itself.
When should sponsors transition to E6(R3) compliance?
There is no universal transition date supplied by this Academy page. Sponsors should follow the implementation status of each applicable authority and assess trial-stage, protocol, contractual, and quality-system implications before changing controlled documents or training.

Continue learning

Explore related topics to deepen your understanding

Get started

Start with the GCP track.

Free to complete, with a record anyone can verify in seconds. Coordinators, monitors, and investigators train here on the current ICH E6(R3) standard.

  • No credit card or hidden trials
  • Verifiable completion record
  • Progress syncs across every device
View the curriculum

Create your account in under a minute